Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).

Matthew D. Galsky, Xiaoliang Yuan, Dingwei Ye et al.|Journal of Clinical Oncology|2025

Cited by 1